Opevesostat vs. NHAStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06136624

Conditions

Prostate Cancer Metastatic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Opevesostat

Abiraterone acetate

Enzalutamide

Hydrocortisone

Fludrocortisone acetate

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-08-24.